Navigation Links
AgriLife Research gets grant to crack biofuel production waste issue
Date:1/10/2013

d lignin.

"The conversion will allow more complete use of carbon in biomass and result in the mitigation of more than 20 million tons of carbon dioxide," Yuan said. "It will also provide another major type of feedstock for biodiesel production, potentially contributing about 10 percent of the total advanced biofuel production.

"The lignin-to-fuel platform would also simplify waste treatment and make refineries more profitable."

The researchers do not have a prediction for when the research will yield marketable results, but Yuan envisions a time when refineries will be able to purchase the newly developed microbes to degrade lignin into a substance usable for fuel production.


'/>"/>

Contact: Kathleen Phillips
ka-phillips@tamu.edu
979-845-2872
Texas A&M AgriLife Communications
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Native orchid protection and conservation subject of new AgriLife Research study
2. BP Biofuels, Texas AgriLife Research sign agreement to advance biofuel feedstock development
3. Researchers identify a new gene with a key role in obesity and diabetes
4. GW researchers find variation in foot strike patterns in predominantly barefoot runners
5. After decades of research, scientists unlock how insulin interacts with cells
6. Mathematics and weather and climate research
7. KAIST and Saudi Aramco agreed to establish a joint CO2 research center in Korea
8. Stem cell materials could boost research into key diseases
9. Surprising teaching tool in K-12 science education -- Zebrafish research
10. F1000Research, the first Open Science publisher, launches following a successful beta testing phase
11. UI researcher learns mechanism of hearing is similar to car battery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
AgriLife Research gets grant to crack biofuel production waste issue
(Date:7/31/2015)... SHENZHEN , Kina, 31. juli 2015 ... ) bliver afholdt af BGI fra den 22. - 25. ... Konferencen fejrer sin 10-års fødselsdag i år. ... verdens mest indflydelsesrige årlige møder på ,omik,-feltet, og er ... forsamlinger. ICG-10 fokuserer på nylige gennembrud ...
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
(Date:7/31/2015)... OXFORD, Conn. , Jul. 31, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies ... technology by introducing a common, uniform way to manage ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... study of 60 beaches in Southern California suggests that ... highest levels when tides are ebbing during the new ... managers better assess the potential risk of swimming. , ... the American Chemical Society's journal Environmental Science & Technology. ...
... a healthy human gene to prevent blindness in mice ... strikes boys. , Writing in the August issue of ... how they successfully used gene therapy in mice to ... from mothers, who retain their sight, to their sons. ...
... a new laser therapy that destroys cancer cells but ... described in a study published in the Aug. 1 ... of Sciences (PNAS). , "One of the longstanding problems ... normal body tissue," says Hongjie Dai, an associate professor ...
Cached Biology News:Beach pollution is worst during new and full moon 2Gene therapy works in mice to prevent blindness that strikes boys 2Gene therapy works in mice to prevent blindness that strikes boys 3Scientists develop nanotech-laser treatment that kills cancer cells without harming healthy tissue 2Scientists develop nanotech-laser treatment that kills cancer cells without harming healthy tissue 3Scientists develop nanotech-laser treatment that kills cancer cells without harming healthy tissue 4
(Date:8/26/2015)... SAN FRANCISCO , Aug. 26, 2015 /PRNewswire/ ... today that it has received a $1.5M Phase ... Health (NIH) to further develop its therapeutic agent ... unmet clinical need in end stage renal disease ... by the National Institute of Diabetes and Digestive ...
(Date:8/26/2015)... CORAL SPRINGS, Florida , August 26, 2015 ... one of the biggest factors fueling the optimism ... FDA approvals, M&A,s, collaborations and life sciences advancements.  ... and developments are Pressure BioSciences, Inc. (OTCQB: PBIO), ... Inc. (NASDAQ: SRPT ), Raptor Pharmaceutical Corp. ...
(Date:8/25/2015)... ... August 25, 2015 , ... Vets Plus, Inc. recently ... The company has added a AS16 Sharples centrifuge to harvest products after fermentation. ... or fungal fermentation process development. , The new centrifuge greatly expands production ...
(Date:8/25/2015)... Doximity, the leading medical network for ... its second annual Residency Navigator , an ... of doctors research and compare residency training programs ... senior medical students used Doximity to research the ... The new Residency Navigator brings an unprecedented level ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7New centrifuge and fermentor expand product development capacity at Vets Plus 2Doximity Releases 2015-2016 Residency Navigator 2Doximity Releases 2015-2016 Residency Navigator 3
... shares of Common Stock in Exchange, for Senior Subordinated and ... ... interest, SEATTLE, Feb. 13 Cell Therapeutics, Inc.,("CTI" or the ... in aggregate principal of its outstanding 5.75%,Convertible Senior Subordinated Notes due 2008 ...
... (Nasdaq:,CEPH) issued the following statement in response to ... Commission (FTC) in U.S. District Court for the,District ... entered,into by the company in late 2005 and ... infringement litigation and seeking to,permanently enjoin the Company ...
... Board Authority to Implement Reverse Stock Split and ... Shares and Authorized Shares, NEW HAVEN, Conn., Feb. 13 ... Special Meeting of,Stockholders was held at the Omni Hotel in ... meeting, shareholders voted to approve amendments to the,Company,s Restated Certificate ...
Cached Biology Technology:Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008 2Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements 2Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements 3Vion Pharmaceuticals Holds Special Meeting of Stockholders 2Vion Pharmaceuticals Holds Special Meeting of Stockholders 3
...
Mouse monoclonal [M2II-12] to MRP2 ( Abpromise for all tested applications). entrezGeneID: 1244 SwissProtID: Q92887...
Mouse monoclonal antibody to ANAPC2 - anaphase promoting complex subunit 2...
... MAX POWER 500V Programmable Power Supply ... which can handle virtually any application ... current blotting. It is unique in ... The MAX POWER Programmable Power Supply ...
Biology Products: